Santhera's idebenone fails in a Phase III trial in Friedreich's ataxia
This article was originally published in Scrip
Executive Summary
Santhera Pharmaceuticals' lead candidate, Catena (idebenone) has failed to meet the primary endpoint of a Phase III trial in Friedreich's ataxia.